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SELECTION OF THE MONTH 
Big Title: Gut-Liver interaction in PSC 
Small titles:  
Sarcopenia and fibrosis in NAFLD 
Trends in global HBV epidemiology 
Dynamics of HCV replication organelles generation 
 
ACUTE LIVER INJURY 
Kruppel-like factor 2 and autophagy cooperate to protect the endothelium  
The transcription factor kruppel-like factor 2 (encoded by KLF2), which is induced by 
simvastatin (among other inducers), promotes endothelial protection. Guixé-Muntet et 
al. hypothesized a role of autophagy in kruppel-like factor 2-mediated endothelial 
protection. They now show that stimulation of autophagy results in kruppel-like factor 
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2 overexpression which accentuates autophagy by a positive feedforward mechanism. 
Acute liver injury caused by ischemia/reperfusion (I/R) inhibits the autophagy/kruppel-
like factor 2 cooperation and results in endothelial cell death. Interestingly, 
simvastatin-pretreatment protects mice against I/R-associated endothelial injury 
because of sustained autophagy and kruppel-like factor 2 expression and 
subsequent endothelial cell survival. Because I/R is an important issue following 
liver transplantation, the findings by Guixé-Muntet and colleagues suggest that 
simvastatin could be useful in preventing this complication. 
 
CHOLESTATIC LIVER DISEASE 
Parsing the phenotype of ABCB11 deficient mice 
Impairment of the canalicular bile acid (BA) transport via the bile salt export pump 
(encoded by ABCB11, also known as BSEP, PFIC2) causes cholestasis. Absence of 
bile salt export pump in humans causes progressive familial intrahepatic cholestasis 
type 2, a severe cholestatic liver disease in children. In contrast to humans, Abcb11 
deficiency in mice is associated with a milder phenotype lacking the development of 
progressive cholestasis. This finding may at least in part be explained by differences 
in BA composition, metabolism and transporters between mice and men. In this issue 
of the Journal, Fuchs et al. addressed the question by investigating wild type and 
Abcb11-/- mice that were subjected to common bile duct ligation or 3.5-
diethoxycarbonyl-1.4dihydrocollidine (DDC) feeding as models for cholestasis with 
biliary obstruction and bile duct injury. They show that mice with inborn Abcb11 
deficiency exhibit an adaptive increase of polyhydroxylated BAs that may 
precondition and thereby protect against acquired cholestatic liver and bile duct 
injury. 
 
CHOLANGIOCARCINOMA 
Cancer stem cells (CSCs) shape tumor-associated macrophages (TAM) 
CSCs play a crucial role in clinical severity of cholangiocarcinoma. Macrophages are 
not only involved in tissue homeostasis and immune defense against pathogens, but 
also can be regulators of cancer, being called TAM in this case. Raggi et al. 
hypothesized that CSCs may induce a tumor-promoting TAM phenotype. They reveal 
that CSCs shape tumor-initiating niche by educating associated macrophages 
via signals such as interleukin (IL)-13 (known to promote M2 phenotype), IL-34 
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(known to stimulate monocytes via the M-CSF receptor) and osteoactivin 
(encoded by GPNMB, for transmembrane glycoprotein NMB, whose functions 
are elusive). 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Dissecting anti-tumor immunity, No touch multi-bipolar radiofrequency vs. 
mono-polar techniques for small HCC 
Dissection of antitumor immunity during tumor initiation and progression has been a 
challenge in the absence of clinically relevant animal models. Li et al. report very 
important new findings in the current issue of the Journal. First, they show that a 
combination of intraperitoneal injection of carbon tetrachloride and intra-splenic 
inoculation of oncogenic hepatocytes is able to induce progressive HCCs in fibrotic 
livers of immunocompetent mice. This model recapitulates main features of human 
HCC. Second, using this new animal model, they find that both immunosuppressive 
regulatory T cell (Treg) accumulation and upregulation of programmed cell death 
protein 1 (i.e., protein PD-1, whose engagement at CD8+ T cell surface inhibits the 
cytotoxic, anti-tumoral action of these cells), are two independent mechanisms 
inducing profound immune tolerance in HCC. Third, using this model, they reveal 
that therapy using a combination of sunitinib (a novel small molecule that blocks 
multiple receptor tyrosine kinase) with antibodies against protein PD-1 achieves 
significant tumor control, supporting translation of this approach for the 
treatment of patients with HCC. 
Although very encouraging results have been reported after treatment of small HCC 
with multi-bipolar radiofrequency ablation (RFA), the mono-polar technique remains 
the most frequently used technique worldwide. Hocquelet et al. compared the rate of 
RFA failure between mono-polar RFA and “No Touch” Multipolar RFA for the curative 
treatment of small HCC (≤5cm) in a large multi-center case-matched study. They show 
that in the context of HCC ≤5 cm, “No Touch” Multipolar RF provides better 
primary success and sustained local tumor response without increasing severe 
complications rates. 
 
NON-ALCOHOLIC STEATOHEPATITIS (NAFLD) 
Effect of aerobic vs resistance physical exercise and role of sarcopenia and 
PARylation 
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Recent studies suggest that sarcopenia is present in many patients with NAFLD. In 
this issue, Koo et al. studied the appendicular skeletal muscle mass (ASM) in a cohort 
of patients with NAFLD. The prevalence of sarcopenia in subjects without NAFLD, 
simple steatosis and NASH were 9%, 18%, and 35%, respectively. The degree of 
sarcopenia inversely correlated with the severity of fibrosis and was associated 
with significant fibrosis independent of body mass index and insulin resistance. 
Moreover, among NAFLD subjects, subjects with sarcopenia were more likely to have 
NASH than those without sarcopenia. This clinical study highlight that sarcopenia is 
associated with severe stages of NAFLD. Further clinical and translational studies 
should reveal the mechanisms and potential non-specific ad targeted therapies. 
Another interesting article in this issue of the Journal comparatively analyzes the 
existing evidence of aerobic (short, more intense) vs. resistance (more maintained) 
exercise in NAFLD. Exercise is a first-line therapy for patients with NAFLD. Hashida et 
al. performed an extensive search of and found 95 published studies on the role of 
exercise in these patients. Aerobic vs resistance exercises were compared. Both 
aerobic and resistance exercise improved hepatic steatosis. No significant 
difference was seen in the duration, frequency, or period of exercise between the two 
exercise groups. However, resistance exercise improves NAFLD with less energy 
consumption. Thus, resistance exercise may be more feasible than aerobic 
exercise for NAFLD patients with poor cardiorespiratory fitness or for those who 
cannot tolerate or participate in aerobic exercise. This study suggests a possible link 
between resistance exercise and lipid metabolism in the liver. 
Finally, an interesting experimental study in this issue reveals a novel mechanism of 
NAFLD that could represent a new therapeutic strategy. Oxidative stress is an 
important feature leading to NAFLD. Because poly-ADP ribosylation (PARylation) 
of proteins by polymerases (PARPs) consumes NAD+, Gariani et al. hypothesized 
that over-activation of PARPs drives NAD+ depletion in NAFLD. To test this 
hypothesis, examined the preventive and therapeutic benefits of the PARP inhibitor, 
olaparib, in different models of NAFLD. PARP inhibition reversed NAFLD by 
repletion of NAD+, and reduced reactive oxygen species, ER-stress and fibrosis. 
This effect was dependent on the activation of sirtuin-1, an epigenetic regulator. This 
interesting study proposes that targeting PARylation could be beneficial in patients with 
NAFLD.   
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HEPATITIS C VIRUS (HCV) INFECTION  
Mortality risk in patients cured from their HCV infection, real-world results of 
sofosbuvir plus daclatasvir in HCV type 1, dynamics of HCV replication 
organelles generation, no evidence for intra-hepatic HCV compartmentalization 
in late stage liver disease 
The number of people living with cured HCV infection is expected to grow rapidly in 
the era of highly effective antiviral regimens. Although treatment-induced cure of the 
infection (sustained virologic response, SVR) is associated with improved patient 
survival, the prognosis after SVR relative to the general population is unclear. The 
study by Innes et al. identified 1,824 patients, followed on average for 5.2 years after 
SVR, using a national Scottish database which includes cause-specific mortality data, 
and compared the frequency of mortality in SVR patients to the general population. 
Overall, all-cause mortality was 1.9 times more frequent for SVR patients than 
the general population, and mainly driven by death from liver cancer and drug-
related causes which accounted for 66% of the total excess death observed. As 
all modifiable characteristics associated with increased mortality were markers of 
either heavy alcohol or injecting drug use, and individuals without these behavioral 
markers (33% of the cohort) experienced equivalent survival to the general population, 
this study highlights the importance of a multidisciplinary approach targeting health risk 
behaviors in the SVR population. Identifying those SVR patients who might benefit 
from regular HCC screening remains a further future challenge.  
In clinical trials the combination of the pan-genotypic NS5A inhibitor daclatasvir with 
the pan-genotypic nucleosidic polymerase inhibitor sofosbuvir has demonstrated high 
antiviral efficacy against chronic HCV infection. Pol et al. report now the first real-world 
results from their French multicenter observational cohort which included 768 HCV 
type 1-infected patients treated with sofosbuvir plus daclatasvir with or without ribavirin 
for a duration of 12 weeks or 24 weeks. The SVR ranged from 92% in the 12-week 
ribavirin-free regimen to 99% in the 24-week ribavirin-containing regimen. A 
greater than 97% SVR rate was observed in patients without cirrhosis irrespective of 
the treatment duration whereas among patients with cirrhosis extending treatment 
duration to 24 weeks increased SVR rates from 88% (12 weeks) to 95%. This large-
scale study confirms the high efficacy of the regimen in the real-life setting but provides 
also relevant information concerning the need for adding ribavirin as well as 
individualizing treatment duration according to the stage of fibrosis. 
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Like all positive-sense RNA viruses, HCV induces cytoplasmic membrane alterations 
in infected cells, which have been termed ‘replication organelles’. The viral 
nonstructural NS5A protein is essential for their formation, and they are believed to be 
sites of HCV RNA synthesis. There remain, however, many questions regarding the 
temporal regulation, turnover and composition of HCV replication organelle function in 
chronically infected cells. In this elegant study, Wang and Tai used a pulse-chase 
fluorescent labeling approach that allows to discriminate ‘old’ from ‘new’ NS5A-positive 
membranous structures (NS5A foci) herby demonstrating that HCV replication 
membrane structures are continuously generated at spatially distinct sites 
supporting a model of continuous de novo replication organelle formation 
instead of resupply of previously-formed ones. Whereas lipid kinase 
phosphatidylinositol 4-kinase IIIα (PI4KA), oxysterol-binding protein (OSBP), and 
NS5A are required to initiate ‘new’ NS5A foci, cholesterol is preferentially trafficked to 
‘old’ NS5A foci and is required for association of ‘old’ foci with HCV core protein and 
lipid droplets. The study provides important new insights in the generation and 
dynamics of viral replication organelles which may be associated with changes in their 
function and morphology, hereby potentially modifying viral infection cycle. 
The primary site of HCV replication is the liver, and recent studies suggest that 1 to 
50% of the hepatocytes are infected. These infected cells occur as clusters surrounded 
by uninfected hepatocytes, supporting a model of intra-hepatic HCV 
compartmentalization, where viral variants may be localized to discrete regions of the 
liver. To investigate the spatial influence of the liver architecture on viral replication, 
and whether local interferon responses may limit HCV replication and evolution, 
Hedegaard et al. measured HCV RNA and interferon-stimulated gene (ISG) 
expression from each of the 8 Couinaud liver segments from 21 patients undergoing 
liver transplantation. The levels of HCV RNA in all eight biopsies sampled from a 
single liver as well as hepatic and plasma viral quasi-species were surprisingly 
similar, suggesting that the liver is uniformly infected during end-stage liver 
disease. By using high resolution HCV sequencing and monitoring of innate immune 
responses at multiple sites across the liver, a uniform pattern of diversity was identified 
which argues against viral compartmentalization. The study also provides novel 
insights into the relationship between hepatic ISG expression and the viral quasi-
species in the liver and periphery. 
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HEPATITIS B VIRUS (HBV) INFECTION 
Long-term safety and efficacy of tenofovir in lamivudine-resistant HBV infection, 
trends in global HBV epidemiology 
Although tenofovir monotherapy has proven activity in lamivudine-resistant HBV 
infection, long-term controlled studies are missing showing its efficacy and safety in 
comparison to a combination approach, an approach which was believed to be more 
effective in the resistance setting. The randomized-controlled study by Fung et al. is 
the first presenting long-term efficacy and safety results, after 5 years of tenofovir 
monotherapy or tenofovir plus emtricitabine combination in 280 patients with 
lamivudine-resistant HBV infection. At week 240 no difference was observed 
between the 2 groups regarding HBV DNA clearance, ALT levels, HBsAg and 
HBeAg loss, and no patient developed resistance-associated mutations in the 
tenofovir monotherapy group. The risk of renal dysfunction was low with a 7% rate 
of confirmed creatinine clearance of less than 50 mL/min. This is also the first study to 
prospectively evaluate changes in bone mineral density (BMD) from baseline using 
serial DEXA scans. The proportion of patients with BMD T-scores consistent with 
osteopenia and osteoporosis increased from baseline to week 240 by 6% points for 
the spine and 8% points for the hip. The study proofs the high efficacy of the 
monotherapy approach with tenofovir in lamivudine-resistant HBV infection, and the 
overall low – but not negligible - risk of mild kidney dysfunction and 
osteopenia/osteoporosis development in the long-term.  
A better knowledge of country-specific trends in HBV prevalence may provide 
important information concerning our previous actions undertaken in order to combat 
this worldwide leading viral infection but will also tell us whether further prevention 
strategies are necessary. Based on published data, Ott et al. applied a linear model on 
the logit scale to assess time trends in estimated HBsAg prevalence in 2000 and their 
relative changes over time by country and region. In most of the 50 countries with 
sufficient data, a decrease in HBsAg prevalence was seen over time. The time 
changes in HBsAg prevalence in the WHO European region revealed four 
different patterns: stable or even increase (Russia, Poland, and Romania), no to 
medium reduction (France, Germany, Israel, the Netherlands, Italy, and Spain), 
medium relative decrease (Albania and Turkey), and strong relative decrease (Greece, 
Slovenia, and United Kingdom). Decreases in HBsAg prevalence occurred mostly 
before direct effects of childhood vaccination may manifest indicating preventive 
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effects of various other health measures. The findings of stable or even increasing 
HBsAg prevalence in some countries of Africa and Eastern Europe underline the 
importance of ongoing and tailored HBV prevention activities and can further assist 
implementing WHO`s prevention and control recommendations. 
 
PRIMARY SCLEROSING CHOLANGITIS 
Memory T-cells of common clonal origin involved in PSC-IBD pathogenesis 
The immunologic mechanisms involved in the pathogenesis of PSC-IBD are unclear 
and the current hypotheses suggest that T-cells recruited into the liver from the gut 
may drive hepatic inflammation. Henriksen et al. studied liver and colonic biopsies to 
determine whether the T-cells obtained from these organs share common receptors 
and antigenic specificities. The authors used high throughput sequencing and 
made the novel observation that in the PSC-IBD patients, memory T-cells of 
common clonal origin was detected in the paired biopsies suggesting that 
memory T-cells driven by shared antigens may be important in the 
pathogenesis. These data allow potentially novel approaches to therapy targeting the 
memory T-cells. 
 
